You are here

Sen-Jam Pharmaceutical Underscores the Urgent Need to Revolutionize Pain Management and End the Opioid Epidemic at the 2019 StartUp Health Festival

HUNTINGTON, N.Y., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Sen-Jam Pharmaceutical, a therapeutic company focused on bringing relief to the opioid crisis, was delighted to present at the 2019 StartUp Health Festival, the premier event during JP Morgan Healthcare that brings together 2,000 entrepreneurs, investors and innovators focused on improving the health and wellbeing of everyone in the world.  Selected to be part of StartUp Health’s exclusive Moonshot Academy for health entrepreneurs, Sen-Jam was among one of the StartUp Health companies that presented their moonshot mission and commitment to ending the Opioid Crisis in America.

Jackie Iversen, Founder and Chief Clinical Officer at Sen-Jam Pharmaceutical, shared with attendees the innovation her team has been pursuing, including their goal “to end the deadliest drug overdose crisis in American history and usher in a new era of pain management that is safe and effective and non-opioid.” Jackie continued, “The number one reason why people remain opioid dependent is because the withdrawal symptoms are too painful.”

Iversen went on to discuss how Exulta-005 may be a revolutionary game-changer in the marketplace because of its uniquely resourceful application of two small molecules.  Iversen had first been inspired to connect the dots between pain and inflammation during her work with Sloan Kettering Cancer Center where she focused solely on pain management.  The same compelling sentiment around the urgency to end the opioid crisis and innovate in the pain space, led her team to consider the role inflammation plays in pain management.

To see more information about the Addiction Moonshot click here.

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical’s Mission is to Create Value by Developing Novel Pharmaceutical Solutions for Large Unmet Needs using the 505(b)2 development pathway.  Sen-Jam’s Exulta® product line is based on Opioid Free Pain Relief with GI Protection for Extended Use.  Sen-Jam Pharmaceutical is focused on providing a new therapeutic solution to the Opioid Crisis.

For more information please visit: www.sen-jam.com.

Christine@sen-jam.com

Wednesday, February 13, 2019 - 08:00